Dolutegravir Remains Superior to Boosted Darunavir for HIV-1Dolutegravir Remains Superior to Boosted Darunavir for HIV-1

Once-daily dolutegravir maintains its higher virological response rates over those of ritonavir-boosted darunavir in treatment-naïve adults with HIV-1 infection, according to 96-week results from the FLAMINGO study. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: HIV/AIDS News Source Type: news